M&A Deal Summary |
|
|---|---|
| Date | 2015-02-17 |
| Target | Immune Targeting Systems |
| Sector | Life Science |
| Buyer(s) | Altimmune |
| Sellers(s) | Truffle Capital |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1997 |
| Sector | Life Science |
| Employees | 59 |
| Revenue | 4M USD (2021) |
Altimmune is an operator of clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. By leveraging specific attributes of its two independent and complementary platform technologies, Altimmune rapidly designs product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. Altimmune was incorporated in 1997 and is based in Gaithersburg, Maryland.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: United Kingdom M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-03-24 |
Avecia - Biodefense vaccines Business
United States
|
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 700M EUR |
| Size | Middle-Market |
| Type | Sector Focused |
Truffle Capital is a French private equity firm focused on majority investments in life science and information technology companies. Within IT, Truffle seeks businesses dealing in mobile content and connectivity, internet, technical software, IT security, and VOIP. Within the life science sector, the Firm looks at opportunities in therapeutic drugs and vaccines, medical devices, as well as other breakthrough technologies. Truffle Capital was formed in 2001 and is based in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 15 of 18 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 6 of 8 |
| Country: United Kingdom M&A | 2 of 2 |
| Year: 2015 M&A | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-02-17 |
Altimmune
Gaithersburg, Maryland, United States Altimmune is an operator of clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. By leveraging specific attributes of its two independent and complementary platform technologies, Altimmune rapidly designs product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. Altimmune was incorporated in 1997 and is based in Gaithersburg, Maryland. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-06-23 |
Abivax
Paris, France Abivax is a clinical-stage company leveraging its antiviral and immune platforms to optimize its drug candidates to cure HIV and treat inflammatory conditions, as well as cancer. Abivax was founded in 2013 and is based in Paris, France. |
Sell | - |
